A Montreal study, to which research member Dr. Moishe Liberman contributed, shows that a drug increases the chances of survival for patients with non-small cell lung cancer (NSCLC), the most common form of lung cancer.
The drug, which restores the anti-tumor immune response, is combined with chemotherapy and administered before surgery.
The results of this study were published in the prestigious New England Journal of Medicine.
Other news
